CN111303045A - Production process of 2-ethoxy-4, 6-difluoropyrimidine - Google Patents
Production process of 2-ethoxy-4, 6-difluoropyrimidine Download PDFInfo
- Publication number
- CN111303045A CN111303045A CN202010199489.5A CN202010199489A CN111303045A CN 111303045 A CN111303045 A CN 111303045A CN 202010199489 A CN202010199489 A CN 202010199489A CN 111303045 A CN111303045 A CN 111303045A
- Authority
- CN
- China
- Prior art keywords
- ethoxy
- difluoropyrimidine
- synthesizing
- dihydroxypyrimidine
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SGVUAJWRAOSPNC-UHFFFAOYSA-N 2-ethoxy-4,6-difluoropyrimidine Chemical compound CCOC1=NC(F)=CC(F)=N1 SGVUAJWRAOSPNC-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004202 carbamide Substances 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims abstract description 6
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940008406 diethyl sulfate Drugs 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 230000002194 synthesizing effect Effects 0.000 claims abstract 11
- 238000010189 synthetic method Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 22
- XAFQKMFFPFLHAC-UHFFFAOYSA-N 2-ethoxy-4-hydroxy-1h-pyrimidin-6-one Chemical compound CCOC1=NC(O)=CC(=O)N1 XAFQKMFFPFLHAC-UHFFFAOYSA-N 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- -1 ethyl isourea sulfate Chemical compound 0.000 claims description 8
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000005660 chlorination reaction Methods 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 239000011698 potassium fluoride Substances 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 235000003270 potassium fluoride Nutrition 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- 238000003682 fluorination reaction Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000012025 fluorinating agent Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CVMAOIALLIBNNZ-UHFFFAOYSA-N 4,6-dichloro-2-ethoxypyrimidine Chemical compound CCOC1=NC(Cl)=CC(Cl)=N1 CVMAOIALLIBNNZ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- BASQEQQOGLYRSJ-UHFFFAOYSA-N 3-pyrrolidin-1-ylsulfonylbenzonitrile Chemical compound C=1C=CC(C#N)=CC=1S(=O)(=O)N1CCCC1 BASQEQQOGLYRSJ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- OKUFUXAMGDXADB-UHFFFAOYSA-N [amino(ethoxy)methylidene]azanium;hydrogen sulfate Chemical compound OS([O-])(=O)=O.CCOC(N)=[NH2+] OKUFUXAMGDXADB-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QOWVDCDOMKPUAL-UHFFFAOYSA-N CC#N.C1CCOC1.CC1=CC=CC=C1 Chemical compound CC#N.C1CCOC1.CC1=CC=CC=C1 QOWVDCDOMKPUAL-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种药物中间体的制备方法,特别是涉及一种2-乙氧基-4,6-二氟嘧啶的制备方法。The invention relates to a preparation method of a pharmaceutical intermediate, in particular to a preparation method of 2-ethoxy-4,6-difluoropyrimidine.
背景技术Background technique
2-乙氧基-4,6-二氟嘧啶是一种重要的嘧啶类化合物,是诸多药物的重要中间体。尤其是合成三唑并嘧啶磺酰胺类药物双氯磺草胺等的关键中间体。2-Ethoxy-4,6-difluoropyrimidine is an important pyrimidine compound and an important intermediate for many drugs. In particular, it is the key intermediate for the synthesis of triazolopyrimidine sulfonamides such as diclofenac.
关于2-乙氧基-4,6-二取代嘧啶类化合物的合成国内外有一些相关报道。其初始原料均是基于2-乙氧基-4,6-二羟基嘧啶进行一些卤代反应条件的优化,以提高产率。而关于2-乙氧基-4,6-二羟基嘧啶的合成现主流合成工艺是基于O-乙基异脲硫酸盐为初始原料进行后续合成以及技术路线改进。而对于工业生产,为了进一步降低成本,提高生产效率,开发更为低成本的生产工艺对于大规模的生产很有必要。There are some related reports at home and abroad about the synthesis of 2-ethoxy-4,6-disubstituted pyrimidines. The starting materials were all based on 2-ethoxy-4,6-dihydroxypyrimidine, and some halogenation reaction conditions were optimized to improve the yield. As for the synthesis of 2-ethoxy-4,6-dihydroxypyrimidine, the current mainstream synthesis process is based on O-ethylisourea sulfate as the initial raw material for subsequent synthesis and technical route improvement. For industrial production, in order to further reduce costs and improve production efficiency, it is necessary to develop a lower-cost production process for large-scale production.
发明内容SUMMARY OF THE INVENTION
本发明的目的是开发一种新的技术路线,提供一种基于尿素为初始原料,开发一种低成本、高收率的2-乙氧基-4,6-二氟嘧啶的新的制备方法。The purpose of this invention is to develop a kind of new technical route, provide a kind of new preparation method of 2-ethoxy-4,6-difluoropyrimidine based on urea as initial raw material, and develop a kind of low cost and high yield .
实现本发明目的的技术方案如下:一种2-乙氧基-4,6-二氟嘧啶的制备方法,具有以下步骤:(1)将尿素与硫酸二乙酯在60-120℃条件下于有机溶剂中反应制备中间体ⅠO-乙基异脲硫酸氢盐;(2)中间体ⅠO-乙基异脲硫酸氢盐制备中间体Ⅱ2-乙氧基-4,6-二羟基嘧啶;(3)中间体Ⅱ2-乙氧基-4,6-二羟基嘧啶碱性条件下经过氯代得到中间体Ⅲ2-乙氧基-4,6-二氯嘧啶;(4)中间体Ⅲ2-乙氧基-4,6-二氯嘧啶与氟代试剂在80-120℃下反应6小时后经分离纯化得到目标产物2-乙氧基-4,6-二氟嘧啶。The technical scheme for realizing the object of the present invention is as follows: a preparation method of 2-ethoxy-4,6-difluoropyrimidine has the following steps: (1) urea and diethyl sulfate are heated at 60-120° C. Reaction in organic solvent to prepare intermediate IO-ethyl isourea hydrogen sulfate; (2) intermediate IO-ethyl isourea hydrogen sulfate to prepare intermediate II 2-ethoxy-4,6-dihydroxypyrimidine; (3) ) Intermediate II 2-ethoxy-4,6-dihydroxypyrimidine undergoes chlorination under basic conditions to obtain intermediate III 2-ethoxy-4,6-dichloropyrimidine; (4) Intermediate III 2-ethoxy The target product 2-ethoxy-4,6-difluoropyrimidine was obtained by separation and purification after -4,6-dichloropyrimidine reacted with fluorinated reagent at 80-120℃ for 6 hours.
上述步骤(1)中所述的尿素与硫酸二甲酯的摩尔比为1∶0.5~1∶1.5;The mol ratio of urea described in above-mentioned steps (1) and dimethyl sulfate is 1: 0.5~1: 1.5;
上述步骤(1)中所述的有机溶剂为乙酸乙酯、四氢呋喃、甲苯、1,2-二氯乙烷、乙腈中的一种或几种的混合体;The organic solvent described in the above-mentioned steps (1) is one or more mixtures in ethyl acetate, tetrahydrofuran, toluene, 1,2-dichloroethane and acetonitrile;
上述步骤(2)中所述的与O-乙基异脲硫酸盐反应的试剂为丙二酸二乙酯;The reagent described in above-mentioned steps (2) and O-ethyl isourea sulfate reaction is diethyl malonate;
上述步骤(2)中所述的O-乙基异脲硫酸盐与丙二酸二乙酯摩尔比为1∶0.5~1∶1.5;The mol ratio of O-ethylisourea sulfate and diethyl malonate described in the above step (2) is 1:0.5~1:1.5;
上述步骤(2)中所述的反应温度为60~150℃;The reaction temperature described in the above-mentioned step (2) is 60~150 ℃;
上述步骤(3)中所述的氯代试剂为三氯氧磷;The chlorination reagent described in above-mentioned steps (3) is phosphorus oxychloride;
上述步骤(3)中所述的碱为三乙胺;The alkali described in above-mentioned steps (3) is triethylamine;
上述步骤(3)中所述的2-乙氧基-4,6-二羟基嘧啶与三氯氧磷的摩尔比为1∶1~1∶3;The mol ratio of 2-ethoxy-4,6-dihydroxypyrimidine and phosphorus oxychloride described in the above step (3) is 1:1~1:3;
上述步骤(3)中所述的2-乙氧基-4,6-二羟基嘧啶与吡啶的摩尔比为1∶2~1∶5;The molar ratio of 2-ethoxy-4,6-dihydroxypyrimidine to pyridine described in the above step (3) is 1:2~1:5;
上述步骤(4)中所述的氟化试剂为氟化钾;The fluorination reagent described in above-mentioned steps (4) is potassium fluoride;
上述步骤(4)中所述的2-乙氧基-4,6-二氯嘧啶与氟化钾的摩尔比为1∶2~1∶5;The mol ratio of 2-ethoxy-4,6-dichloropyrimidine and potassium fluoride described in the above step (4) is 1:2~1:5;
本发明与现有技术相比具有明显的积极效果:本发明采用尿素为初始原料,生产安全性好,收率稳定,原料转化率高,后处理方便,综合考察有效的降低了2-乙氧基-4,6-二氟嘧啶的生产成本,最终产物为白色晶体,纯度为大于99%,每步收率基本均大于80%,经过四步后总收率可达到61%以上;本发明过程中使用的溶剂可回收,进一步降低生产成本,适合工业化生产。Compared with the prior art, the present invention has obvious positive effects: the present invention adopts urea as the initial raw material, has good production safety, stable yield, high conversion rate of raw materials, convenient post-processing, and effectively reduces 2-ethoxylate after comprehensive investigation. The production cost of base-4,6-difluoropyrimidine, the final product is white crystal, the purity is more than 99%, the yield of each step is basically more than 80%, and the total yield can reach more than 61% after four steps; the present invention The solvent used in the process can be recovered, which further reduces the production cost and is suitable for industrial production.
具体实施方式Detailed ways
以下所述仅为本发明的较佳实施例,并不因此限定本发明的保护范围。The following descriptions are only preferred embodiments of the present invention, and therefore do not limit the protection scope of the present invention.
实施例1:本实施例为O-乙基异脲硫酸氢盐的制备,具体方法如下:Embodiment 1: the present embodiment is the preparation of O-ethyl isourea hydrogen sulfate, and the concrete method is as follows:
将尿素(129g,2.148mol),硫酸二乙酯(280g,1.818mol)加入1000ml反应瓶中搅拌均匀,80℃条件下反应6小时,取样分析至尿素≤0.5%时停止反应。通过减压蒸馏除去反应体系多余硫酸二乙酯,所得剩余固体,利用乙酸乙酯洗涤提纯得到产物O-乙基异脲硫酸氢盐301.5g,收率75.5%,纯度为99.2%(HPLC);Add urea (129g, 2.148mol) and diethyl sulfate (280g, 1.818mol) into a 1000ml reaction flask and stir well, react at 80°C for 6 hours, stop the reaction when sampling and analysis to urea≤0.5%. The excess diethyl sulfate in the reaction system was removed by distillation under reduced pressure, and the remaining solid obtained was washed and purified with ethyl acetate to obtain the product O-ethylisourea hydrogen sulfate 301.5g, the yield was 75.5%, and the purity was 99.2% (HPLC);
实施例2-5;Embodiment 2-5;
各实施例的方法与实施例1基本相同,不同之处见表1;The method of each embodiment is basically the same as that of embodiment 1, and the difference is shown in Table 1;
表1其它条件影响Table 1 Other conditions affect
实施例6:本实施例为2-乙氧基-4,6-二羟基嘧啶的制备,具体方法如下:Embodiment 6: This embodiment is the preparation of 2-ethoxy-4,6-dihydroxypyrimidine, and the specific method is as follows:
在1000mL反应瓶中加入93.5g纯度为99.5%的O-乙基异脲硫酸氢盐(0.5mol)和250g的无水甲醇,将该体系冷却到-5℃,搅拌下滴加200g浓度为27wt%的甲醇钠溶液,滴加完毕后室温反应0.5h。在-5℃条件下通过缓慢滴加的方式(约20min)加入87.6g丙二酸二乙酯,滴加完毕后20℃反应6h。取样分析至O-乙基异脲硫酸氢盐≤0.5%时停止反应。减压蒸馏回收反应体系中的甲醇,随后向体系中加入水充分溶解,冷却至5℃以下,搅拌条件下滴加30g浓度为36.5%的盐酸调节pH至2,待固体充分析出后过滤、水洗、干燥得到69.2g的2-乙氧基-4,6-二羟基嘧啶白色晶体,收率为88.7%,纯度为99.4%(HPLC)。93.5g of O-ethylisourea hydrogen sulfate (0.5mol) with a purity of 99.5% and 250g of anhydrous methanol were added to a 1000mL reaction flask, the system was cooled to -5°C, and 200g of 27wt concentration was added dropwise with stirring. % sodium methoxide solution, and react at room temperature for 0.5h after the dropwise addition. 87.6 g of diethyl malonate was added by slow dropwise addition (about 20 min) at -5 °C, and the reaction was performed at 20 °C for 6 h after the dropwise addition. Sampling and analysis to stop the reaction when O-ethylisourea hydrogen sulfate is less than or equal to 0.5%. The methanol in the reaction system was recovered by distillation under reduced pressure, and then water was added to the system to fully dissolve, cooled to below 5°C, and 30 g of hydrochloric acid with a concentration of 36.5% was added dropwise under stirring to adjust the pH to 2. After the solid was fully separated, filter and wash with water. , and dried to obtain 69.2 g of 2-ethoxy-4,6-dihydroxypyrimidine white crystals with a yield of 88.7% and a purity of 99.4% (HPLC).
实施例7:本实施例为2-乙氧基-4,6-二氯嘧啶的制备,具体方法如下:Embodiment 7: This embodiment is the preparation of 2-ethoxy-4,6-dichloropyrimidine, and the specific method is as follows:
在1000mL反应瓶中将157g纯度为99.4%(1mol)的2-乙氧基-4,6-二羟基嘧啶溶于1,2-二氯乙烷(300mL)中,向体系中缓慢加入三氯氧磷340g(2.2mol)。反应体系在搅拌下加入纯度为98.5%的三乙胺205g(2mol),在加入三乙胺的过程中,注意控制滴加速度和反应体系温度,使反应液温度不超过50℃。添加完毕后,反应体系至85℃反应3h,取样分析至2-乙氧基-4,6-二羟基嘧啶≤0.5%时停止反应。冷却至室温,缓慢加入适量冰水后搅拌0.5h,静置分层,有机相经过盐水水洗一次后,干燥,分馏后得到产品174.2g,收率90.7%,纯度为98.7%(HPLC)。In a 1000mL reaction flask, 157g of 2-ethoxy-4,6-dihydroxypyrimidine with a purity of 99.4% (1mol) was dissolved in 1,2-dichloroethane (300mL), and trichloroethylene was slowly added to the system. Phosphorus 340 g (2.2 mol). 205 g (2 mol) of triethylamine with a purity of 98.5% was added to the reaction system under stirring. During the process of adding triethylamine, attention was paid to controlling the rate of addition and the temperature of the reaction system so that the temperature of the reaction solution did not exceed 50°C. After the addition was completed, the reaction system was reacted at 85° C. for 3 h, and the reaction was stopped when 2-ethoxy-4,6-dihydroxypyrimidine ≤ 0.5% was sampled and analyzed. Cooled to room temperature, slowly added an appropriate amount of ice water, stirred for 0.5h, left to stand for layers, the organic phase was washed once with brine, dried, and fractionated to obtain 174.2g of the product, yield 90.7%, purity 98.7% (HPLC).
实施例8-12;Embodiment 8-12;
各实施例的方法与实施例7基本相同,不同之处见表2;The method of each embodiment is basically identical with embodiment 7, and difference is shown in Table 2;
表2其它条件影响Table 2 Other conditions affect
实施例13:本实施例为2-乙氧基-4,6-二氟嘧啶的制备,具体方法如下:Embodiment 13: This embodiment is the preparation of 2-ethoxy-4,6-difluoropyrimidine, and the specific method is as follows:
在1000mL反应瓶中加入400mL环丁砜,纯度为98.5%的无水氟化钾147.2g(2.5mol),加热至200℃搅拌1h。然后冷却到80℃,加入纯度为98.7%的2-乙氧基-4,6-二氯嘧啶194.5g(1mol),升温至160℃,搅拌反应3h。取样分析至2-乙氧基-4,6-二氯基嘧啶≤0.5%时停止反应,减压蒸馏蒸出产品,重新分馏得到产品132.3g,收率82.7%,纯度为99.1%(HPLC)。冷却下可形成白色结晶。In a 1000 mL reaction flask, 400 mL of sulfolane, 147.2 g (2.5 mol) of anhydrous potassium fluoride with a purity of 98.5% was added, and the mixture was heated to 200° C. and stirred for 1 h. Then it was cooled to 80°C, 194.5 g (1 mol) of 2-ethoxy-4,6-dichloropyrimidine with a purity of 98.7% was added, the temperature was raised to 160°C, and the reaction was stirred for 3 hours. Sampling and analysis to stop the reaction when 2-ethoxy-4,6-dichloropyrimidine is less than or equal to 0.5%, the product is distilled off under reduced pressure, and the product is refractionated to obtain 132.3g, the yield is 82.7%, and the purity is 99.1% (HPLC) . White crystals may form on cooling.
实施例14-19;Examples 14-19;
各实施例的方法与实施例13基本相同,不同之处见表3;The method of each embodiment is basically the same as that of embodiment 13, and the difference is shown in Table 3;
表3其它条件影响Table 3 Other conditions affect
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019111694555 | 2019-11-25 | ||
CN201911169455 | 2019-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111303045A true CN111303045A (en) | 2020-06-19 |
Family
ID=71151429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010199489.5A Pending CN111303045A (en) | 2019-11-25 | 2020-03-19 | Production process of 2-ethoxy-4, 6-difluoropyrimidine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111303045A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114262300A (en) * | 2021-12-15 | 2022-04-01 | 浙江伟锋药业有限公司 | Preparation method of 2-ethoxy-4, 6-difluoropyrimidine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463055A (en) * | 1992-12-24 | 1995-10-31 | Skw Trostberg Aktiengesellschaft | Process for the production of 2-ethoxy-4,6-dihydroxypyrimidine or its alkali salts |
US5552546A (en) * | 1994-07-28 | 1996-09-03 | Dowelanco | Process for the preparation of 2-ethoxy-4,6-dihydroxypyrimidine |
CN102250018A (en) * | 2011-05-19 | 2011-11-23 | 江苏省农用激素工程技术研究中心有限公司 | Preparation method of 2-ehtyoxyl-4,6-dyhydroxypyrimidine |
CN103483273A (en) * | 2013-09-12 | 2014-01-01 | 浙江工业大学 | 6-methyl-5-fluorine-2,4-pyrimidinediamine compound and preparation and application thereof |
CN105669496A (en) * | 2016-03-04 | 2016-06-15 | 湖南化工研究院有限公司 | Preparation method of O-methyl isourea sulphate |
CN106632080A (en) * | 2016-08-25 | 2017-05-10 | 宿迁市万和泰化工有限公司 | Flucytosine manufacturing process |
CN108047094A (en) * | 2017-12-19 | 2018-05-18 | 湖北远大富驰医药化工股份有限公司 | A kind of O- methyl-isoureas Methylsulfate novel preparation method |
-
2020
- 2020-03-19 CN CN202010199489.5A patent/CN111303045A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463055A (en) * | 1992-12-24 | 1995-10-31 | Skw Trostberg Aktiengesellschaft | Process for the production of 2-ethoxy-4,6-dihydroxypyrimidine or its alkali salts |
US5552546A (en) * | 1994-07-28 | 1996-09-03 | Dowelanco | Process for the preparation of 2-ethoxy-4,6-dihydroxypyrimidine |
CN102250018A (en) * | 2011-05-19 | 2011-11-23 | 江苏省农用激素工程技术研究中心有限公司 | Preparation method of 2-ehtyoxyl-4,6-dyhydroxypyrimidine |
CN103483273A (en) * | 2013-09-12 | 2014-01-01 | 浙江工业大学 | 6-methyl-5-fluorine-2,4-pyrimidinediamine compound and preparation and application thereof |
CN105669496A (en) * | 2016-03-04 | 2016-06-15 | 湖南化工研究院有限公司 | Preparation method of O-methyl isourea sulphate |
CN106632080A (en) * | 2016-08-25 | 2017-05-10 | 宿迁市万和泰化工有限公司 | Flucytosine manufacturing process |
CN108047094A (en) * | 2017-12-19 | 2018-05-18 | 湖北远大富驰医药化工股份有限公司 | A kind of O- methyl-isoureas Methylsulfate novel preparation method |
Non-Patent Citations (1)
Title |
---|
陶贤鉴,等: "2-乙氧基-4,6-二氟嘧啶的合成", 《农药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114262300A (en) * | 2021-12-15 | 2022-04-01 | 浙江伟锋药业有限公司 | Preparation method of 2-ethoxy-4, 6-difluoropyrimidine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020147861A1 (en) | Electrochemical preparation method for β-trifluoromethylamide compound | |
US9611226B2 (en) | Preparation method for azoxystrobin | |
CN104844412B (en) | A kind of preparation method of 1,2,4-trifluoro-benzene | |
CN111018740B (en) | Synthesis method of 4-bromo-2-cyano-5-fluorobenzoic acid methyl ester | |
CN107641106A (en) | The synthetic method of Favipiravir intermediate and Favipiravir | |
CN101717368A (en) | Method and process thereof for preparing imidazole ionic liquid under microwave condition | |
CN107936029B (en) | Method for synthesizing Ribociclib | |
US10005726B2 (en) | Ribociclib intermediate and preparation method therefor | |
CN102167716B (en) | Synthesis method of clofarabine, midbody thereof and preparation method of midbody | |
CN106632014B (en) | A kind of preparation method of 2-amino-5-chloropyridine | |
CN105330598A (en) | Preparing method for pirfenidone | |
CN111303045A (en) | Production process of 2-ethoxy-4, 6-difluoropyrimidine | |
CN110698352B (en) | A kind of synthetic method of 3-bromo-5-aminocatechol dimethyl ether | |
CN104650093A (en) | Synthesis method of sildenafil analog | |
CN112939893A (en) | Synthesis method of 4- (4-aminophenyl) -3-morpholinone | |
CN110950778A (en) | Process and catalyst system for preparing aromatic malononitrile | |
CN109761914B (en) | Method for preparing 5-trifluoromethyl uracil | |
CN108409557A (en) | Bu Waxitan new intermediates and its synthetic method and application | |
JP2001247522A (en) | Method of preparing quaternary alkylammonium tetrafluoroborates | |
CN115819298A (en) | Preparation method and application of p-toluenesulfonylmethyl isonitrile | |
CN111574384B (en) | Preparation method of chiral 1-amino-2-propanol | |
CN110054558B (en) | Preparation method of 1-trifluoromethylcyclopropane-1-formic acid | |
CN115521209A (en) | Synthesis method of benzyltriethylammonium chloride | |
CN106883147B (en) | A kind of preparation method of phenyl-pentafluoride formonitrile HCN | |
CN101747343B (en) | A kind of preparation method of sulbactam pivoxil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200619 |
|
WD01 | Invention patent application deemed withdrawn after publication |